Published in Arch Dermatol on March 01, 2000
Using dermoscopic criteria and patient-related factors for the management of pigmented melanocytic nevi. Arch Dermatol (2009) 1.05
Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol (2009) 0.93
Common acquired nevomelanocytic nevi and the fourth dimension. Arch Dermatol (2000) 0.78
Mechanical properties of growing melanocytic nevi and the progression to melanoma. PLoS One (2014) 0.78
Growth-Curve Modeling of Nevi With a Peripheral Globular Pattern. JAMA Dermatol (2015) 0.76
Streamlining cutaneous melanomas in young women of the Belgian Mosan region. Biomed Res Int (2014) 0.76
Changes even in benign melanocytic nevi. Arch Dermatol (2001) 0.75
Enlarging common melanocytic nevi and the diagnosis of malignant melanoma. Arch Dermatol (2001) 0.75
The study of nevi in children: Principles learned and implications for melanoma diagnosis. J Am Acad Dermatol (2016) 0.75
Spitz and Reed nevi: acquired or congenital? Dermatol Pract Concept (2012) 0.75
Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene (2017) 0.75
Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A (1996) 6.29
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development (1999) 4.21
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97
Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J Virol (2000) 3.77
The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell (1996) 3.55
Cyclic amplification and selection of targets (CASTing) for the myogenin consensus binding site. Mol Cell Biol (1991) 3.54
Epidermal Langerhans cells--a target for HTLV-III/LAV infection. J Invest Dermatol (1987) 3.41
Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol (1995) 3.34
Epidermal Langerhans cells bear Fc and C3 receptors. Nature (1977) 3.21
Diagnostic accuracy of dermoscopy. Lancet Oncol (2002) 3.14
Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med (1987) 3.13
Complications following the use of the Combitube, tracheal tube and laryngeal mask airway. Anaesthesia (1999) 2.72
Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet (1997) 2.64
Alternaria redefined. Stud Mycol (2013) 2.56
Impact of landscape management on the genetic structure of red squirrel populations. Science (2001) 2.34
PCR and blood culture for detection of Escherichia coli bacteremia in rats. J Clin Microbiol (1999) 2.28
Ultraviolet light depletes surface markers of Langerhans cells. J Invest Dermatol (1981) 2.28
Expression of Thy-1 antigen by murine epidermal cells. J Invest Dermatol (1983) 2.20
Phototesting and dosimetry for photochemotherapy. Br J Dermatol (1977) 2.17
Noninvasive assessment of cardiac output in critically ill patients by analysis of the finger blood pressure waveform. Crit Care Med (1997) 2.00
In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol (1987) 1.90
Two independent peroxisomal targeting signals in catalase A of Saccharomyces cerevisiae. J Cell Biol (1993) 1.86
Ecstasy pill testing: harm minimization gone too far? Addiction (2001) 1.85
Risks and benefits of sequential imaging of melanocytic skin lesions in patients with multiple atypical nevi. Arch Dermatol (2001) 1.84
Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob Agents Chemother (1996) 1.83
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol (1998) 1.82
Comparing three-class diagnostic tests by three-way ROC analysis. Med Decis Making (2000) 1.80
The fine structure of the Langerhans cell granule. J Cell Biol (1967) 1.79
Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. Br J Dermatol (2001) 1.77
Coloidal gold, ferritin and peroxidase as markers for electron microscopic double labeling lectin techniques. J Histochem Cytochem (1978) 1.77
Evidence of HLA-DR antigen biosynthesis by human keratinocytes in disease. J Exp Med (1984) 1.75
Automated melanoma recognition. IEEE Trans Med Imaging (2001) 1.71
Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 1.68
The langerhans cell. Curr Probl Dermatol (1972) 1.67
Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol (1988) 1.62
Methadone maintenance and tuberculosis treatment. BMJ (1996) 1.61
Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J Invest Dermatol (1991) 1.60
Antigen presentation by murine epidermal langerhans cells and its alteration by ultraviolet B light. J Immunol (1981) 1.60
Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol (1997) 1.60
Pip2p: a transcriptional regulator of peroxisome proliferation in the yeast Saccharomyces cerevisiae. EMBO J (1996) 1.58
Human epidermal T cells predominantly belong to the lineage expressing alpha/beta T cell receptor. J Exp Med (1990) 1.57
Ultrastructural localization of immunoglobulins in bullous pemphigoid skin. Employment of a new peroxidase-antiperoxidase multistep method. J Invest Dermatol (1975) 1.57
Uptake, intracellular transport and degradation of exogenous protein by Langerhans cells. An electron microscopic-cytochemical study using peroxidase as tracer substance. J Invest Dermatol (1970) 1.56
Permeability of the epidermis and the phagocytic activity of keratinocytes. Ultrastructural studies with thorotrast as a marker. J Ultrastruct Res (1971) 1.55
Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction. Eur Heart J (1996) 1.54
103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys (1996) 1.53
Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood (1998) 1.53
[Odland bodies (Membrane coating granules, keratinosomes) as epidermal lysosomes. An electron microscopic-cytochemical contribution on the cornification process of the skin]. Arch Klin Exp Dermatol (1967) 1.51
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med (1998) 1.50
Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. Eur J Cancer (1998) 1.48
Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol (1990) 1.47
Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem (1998) 1.47
Cimetidine versus intensive antacid therapy for duodenal ulcer: a multicenter trial. Gastroenterology (1978) 1.47
Hemodynamic and catecholamine stress responses to insertion of the Combitube, laryngeal mask airway or tracheal intubation. Anesth Analg (1999) 1.44
Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J Invest Dermatol (1991) 1.43
Skin tumors in the European PUVA Study. Eight-year follow-up of 1,643 patients treated with PUVA for psoriasis. J Am Acad Dermatol (1987) 1.42
Erythema multiforme associated human autoantibodies against desmoplakin I and II: biochemical characterization and passive transfer studies into newborn mice. J Invest Dermatol (1998) 1.41
Statistical evaluation of epiluminescence microscopy criteria for melanocytic pigmented skin lesions. J Am Acad Dermatol (1993) 1.41
Substance misuse among health care workers: national survey of occupational physicians. Occup Med (Lond) (2012) 1.40
Severe sun sensitivity and the presence of antinuclear antibodies in patients with polymorphous light eruption-like lesions. A form fruste of photosensitive lupus erythematosus? J Am Acad Dermatol (1992) 1.40
Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica (1996) 1.38
[Photochemotherapy of psoriasis: clinical experiences with 152 patients (author's transl)]. Dtsch Med Wochenschr (1975) 1.38
Molecular analysis of plant migration and refugia in the Arctic. Science (2000) 1.37
A study of the chromosomes of the yeast Schizosaccharomyces pombe by light and electron microscopy. Exp Cell Res (1975) 1.36
Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med (1999) 1.35
Control of peroxisome proliferation in Saccharomyces cerevisiae by ADR1, SNF1 (CAT1, CCR1) and SNF4 (CAT3). Yeast (1992) 1.35
Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol (1995) 1.34
The Saccharomyces cerevisiae peroxisomal 2,4-dienoyl-CoA reductase is encoded by the oleate-inducible gene SPS19. J Biol Chem (1997) 1.32
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Quantitative studies on the Langerhans cell population of guinea pig epidermis. J Invest Dermatol (1967) 1.31
[The Langerhans cells. Results of newer experimental studies. I]. Arch Klin Exp Dermatol (1967) 1.30
Langerhans cells as stimulator cells in the murine primary epidermal cell-lymphocyte reaction: alteration by UV-B irradiation. J Invest Dermatol (1982) 1.30
Langerhans' cells are an actual site of HIV-1 replication. Intervirology (1988) 1.27
Generalized atrophic benign epidermolysis bullosa. Arch Dermatol (1982) 1.27
P45, an extracellular 45 kDa protein of Listeria monocytogenes with similarity to protein p60 and exhibiting peptidoglycan lytic activity. Arch Microbiol (2000) 1.27
Streptococcus suis infections in Danish pigs and experimental infection with Streptococcus suis serotype 7. Acta Pathol Microbiol Immunol Scand B (1987) 1.27
Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. J Immunol (1997) 1.25
An electron microscopic study on the extraneous coat of keratinocytes and the intercellular space of the epidermis. J Invest Dermatol (1968) 1.24
Core-binding factor: a central player in hematopoiesis and leukemia. Cancer Res (1999) 1.23
Ultrastructural localization of nucleoside triphosphatase in Langerhans cells. J Invest Dermatol (1967) 1.22
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21
Cannabis use in patients with multiple sclerosis. Mult Scler (2006) 1.21
Ultrastructural localization of pemphigus autoantibodies within e epidermis. Nature (1971) 1.21
Mechanism of UV-B-induced impairment of the antigen-presenting capacity of murine epidermal cells. J Immunol (1983) 1.20
Induction of UV light tolerance by PUVA in patients with polymorphous light eruption. Br J Dermatol (1978) 1.20